A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
via Google News
The Latest on: Retinitis pigmentosa
- jCyte Inc. Announces Scientific Advisory Board with Distinguished Retinal Physicianson June 30, 2020 at 7:42 pm
Cyte Inc., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory Board (SAB) comprised of world-renowned ...
- SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophieson June 30, 2020 at 7:00 am
SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophies ...
- Researchers develop artificial liquid retinal prosthesis to counteract the effects of eye disorderson June 29, 2020 at 11:07 pm
Researchers at IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) has led to the revolutionary development of an artificial liquid retinal prosthesis to counteract the effects of ...
- ReNeuron Announces Further Positive Data in Retinal Clinical Trialon June 29, 2020 at 1:34 pm
PRNewswire/ -- ReNeuron Group plc (AIM:RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing ...
- Injectable Liquid Prosthesis to Treat Retinal Diseases Developedon June 29, 2020 at 1:10 pm
Retinal prostheses promise the restoration of vision to people with age-related macular degeneration, retinitis pigmentosa, and other conditions that lead ...
- Nanotechnology applied to medicine: The first liquid retina prosthesison June 29, 2020 at 10:06 am
Research at IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) has led to the revolutionary development of an artificial liquid retinal prosthesis to counteract the effects of ...
- UB research contributes to rethinking of what leads to rare disorder causing blindnesson June 26, 2020 at 4:39 am
UB scientist Steven Fliesler and his colleagues report findings that challenge what was previously believed to cause a form of retinitis pigmentosa.
- Researcher's work contributes to a rethinking of what leads to a rare disorder causing blindnesson June 24, 2020 at 7:12 am
A series of papers published recently by two teams of vision researchers at the University at Buffalo and the University of Alabama at Birmingham (UAB) is revealing important new information about the ...
- Retinitis Pigmentosa (RP): Global Market Insights, Epidemiology and Forecast to 2030on June 24, 2020 at 4:50 am
Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the disease, historical ...
- Triangle leaders highlight diversity's positive effect on revenues, loyaltyon June 23, 2020 at 1:00 pm
Triangle business leaders said inclusive work environments lead to higher revenues, greater productivity and stronger loyalty.
via Bing News